Mudit Chowdhary1, Jeffrey M Switchenko2, Robert H Press3, Jaymin Jhaveri3, Zachary S Buchwald3, Philip A Blumenfeld4, Gaurav Marwaha4, Aidnag Diaz4, Dian Wang4, Ross A Abrams4, Jeffrey J Olson5, Hui-Kuo G Shu3, Walter J Curran3, Kirtesh R Patel6. 1. Department of Radiation Oncology, Rush University Medical Center, 500 South Paulina, Chicago, IL, 60612, USA. mchowdharymd@gmail.com. 2. Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA, USA. 3. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. 4. Department of Radiation Oncology, Rush University Medical Center, 500 South Paulina, Chicago, IL, 60612, USA. 5. Department of Neurosurgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA. 6. Department of Therapeutic Radiology and Smilow Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA. kirtesh@gmail.com.
Abstract
INTRODUCTION: Neutrophil-to-lymphocyte ratio (NLR) is a surrogate for systemic inflammatory response and its elevation has been shown to be a poor prognostic factor in various malignancies. Stereotactic radiosurgery (SRS) can induce a leukocyte-predominant inflammatory response. This study investigates the prognostic impact of post-SRS NLR in patients with brain metastases (BM). METHODS: BM patients treated with SRS from 2003 to 2015 were retrospectively identified. NLR was calculated from the most recent full blood counts post-SRS. Overall survival (OS) and intracranial outcomes were calculated using the Kaplan-Meier method and cumulative incidence with competing risk for death, respectively. RESULTS: 188 patients with 328 BM treated with SRS had calculable post-treatment NLR values. Of these, 51 (27.1%) had a NLR > 6. The overall median imaging follow-up was 13.2 (14.0 vs. 8.7 for NLR ≤ 6.0 vs. > 6.0) months. Baseline patient and treatment characteristics were well balanced, except for lower rate of ECOG performance status 0 in the NLR > 6 cohort (33.3 vs. 44.2%, p = 0.026). NLR > 6 was associated with worse 1- and 2-year OS: 59.9 vs. 72.9% and 24.6 vs. 43.8%, (p = 0.028). On multivariable analysis, NLR > 6 (HR: 1.53; 95% CI 1.03-2.26, p = 0.036) and presence of extracranial metastases (HR: 1.90; 95% CI 1.30-2.78; p < 0.001) were significant predictors for worse OS. No association was seen with NLR and intracranial outcomes. CONCLUSION: Post-treatment NLR, a potential marker for post-SRS inflammatory response, is inversely associated with OS in patients with BM. If prospectively validated, NLR is a simple, systemic marker that can be easily used to guide subsequent management.
INTRODUCTION: Neutrophil-to-lymphocyte ratio (NLR) is a surrogate for systemic inflammatory response and its elevation has been shown to be a poor prognostic factor in various malignancies. Stereotactic radiosurgery (SRS) can induce a leukocyte-predominant inflammatory response. This study investigates the prognostic impact of post-SRS NLR in patients with brain metastases (BM). METHODS: BM patients treated with SRS from 2003 to 2015 were retrospectively identified. NLR was calculated from the most recent full blood counts post-SRS. Overall survival (OS) and intracranial outcomes were calculated using the Kaplan-Meier method and cumulative incidence with competing risk for death, respectively. RESULTS: 188 patients with 328 BM treated with SRS had calculable post-treatment NLR values. Of these, 51 (27.1%) had a NLR > 6. The overall median imaging follow-up was 13.2 (14.0 vs. 8.7 for NLR ≤ 6.0 vs. > 6.0) months. Baseline patient and treatment characteristics were well balanced, except for lower rate of ECOG performance status 0 in the NLR > 6 cohort (33.3 vs. 44.2%, p = 0.026). NLR > 6 was associated with worse 1- and 2-year OS: 59.9 vs. 72.9% and 24.6 vs. 43.8%, (p = 0.028). On multivariable analysis, NLR > 6 (HR: 1.53; 95% CI 1.03-2.26, p = 0.036) and presence of extracranial metastases (HR: 1.90; 95% CI 1.30-2.78; p < 0.001) were significant predictors for worse OS. No association was seen with NLR and intracranial outcomes. CONCLUSION:Post-treatment NLR, a potential marker for post-SRS inflammatory response, is inversely associated with OS in patients with BM. If prospectively validated, NLR is a simple, systemic marker that can be easily used to guide subsequent management.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Muthuraman Alagappan; Erqi L Pollom; Rie von Eyben; Margaret M Kozak; Sonya Aggarwal; George A Poultsides; Albert C Koong; Daniel T Chang Journal: Am J Clin Oncol Date: 2018-03 Impact factor: 2.339
Authors: Antoine Louveau; Igor Smirnov; Timothy J Keyes; Jacob D Eccles; Sherin J Rouhani; J David Peske; Noel C Derecki; David Castle; James W Mandell; Kevin S Lee; Tajie H Harris; Jonathan Kipnis Journal: Nature Date: 2015-06-01 Impact factor: 49.962
Authors: Nikhil T Sebastian; Rohit Raj; Rahul Prasad; Christian Barney; Jeremy Brownstein; John Grecula; Karl Haglund; Meng Xu-Welliver; Terence M Williams; Jose G Bazan Journal: Front Oncol Date: 2020-11-05 Impact factor: 6.244
Authors: Beat Bojaxhiu; Arnoud J Templeton; Olgun Elicin; Mohamed Shelan; Kathrin Zaugg; Marc Walser; Roland Giger; Daniel M Aebersold; Alan Dal Pra Journal: Radiat Oncol Date: 2018-11-06 Impact factor: 3.481
Authors: Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram Journal: Theranostics Date: 2019-07-09 Impact factor: 11.556
Authors: Matthias Schneider; Niklas Schäfer; Christian Bode; Valeri Borger; Lars Eichhorn; Frank A Giordano; Erdem Güresir; Muriel Heimann; Yon-Dschun Ko; Felix Lehmann; Anna-Laura Potthoff; Alexander Radbruch; Christina Schaub; Katjana S Schwab; Johannes Weller; Hartmut Vatter; Ulrich Herrlinger; Jennifer Landsberg; Patrick Schuss Journal: J Clin Med Date: 2021-02-07 Impact factor: 4.241
Authors: Celine Garrett; Therese M Becker; David Lynch; Joseph Po; Wei Xuan; Kieran F Scott; Paul de Souza Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240
Authors: Anna Cho; Helena Untersteiner; Fabian Fitschek; Farjad Khalaveh; Philip Pruckner; Noemi Pavo; Karl Rössler; Christian Dorfer; Brigitte Gatterbauer; Christoph Höller; Manuela Schmidinger; Josa M Frischer Journal: J Neurooncol Date: 2021-06-20 Impact factor: 4.130